Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 9/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27965302 | 0.75 | SLC9A1 (0.43) | SLC9A1KEAP1ATMKDM5AKDM4C | |
| SCHEMBL2914480 | 0.71 | MAPT (0.46) | SLC9A1KEAP1MPOSLC2A1KDM4E | |
| SCHEMBL147219 | 0.71 | SLC9A1 (0.43) | SLC9A1KEAP1ATMMPOSLC2A1 | |
| SCHEMBL2673505 | 0.69 | SLC9A1 (0.42) | SLC9A1KEAP1ATMKDM5AKDM4C | |
| SCHEMBL13067164 | 0.69 | ESR2 (0.49) | SLC9A1KEAP1ATMMPOSLC2A1 | |
| SCHEMBL17831574 | 0.69 | MPO (0.42) | SLC9A1KEAP1ATMKDM5AKDM4C | |
| Ammonia Solution, Strong SCHEMBL27710165 | 0.69 | SLC9A1 (0.42) | SLC9A1KEAP1ATMMPOSLC2A1 | |
| SCHEMBL16815570 | 0.69 | ATM (0.45) | SLC9A1KEAP1ATMKDM5AKDM4C | |
| SCHEMBL7580249 | 0.68 | KDM5A (0.48) | SLC9A1KEAP1ATMKDM5AKDM4C | |
| SCHEMBL3712946 | 0.68 | MPO (0.45) | SLC9A1KEAP1ATMMPOSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8791095-B2 | Steroidal CYP17 inhibitors/antiandrogens | TOKAI PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010091303-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312924-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | SLC9A1 2619/4885KEAP1 377/4885ATM 2807/4885 |
| US-20150051179-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP11B1, HSD17B7, CYP17A1 | SLC9A1 2619/4885KEAP1 377/4885ATM 2807/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | SLC9A1 3735/4885KEAP1 251/4885ATM 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.